Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors

References

• Seth S, Ager A, Arends MJ, Frayling IM. Lynch syndrome - cancer pathways, heterogeneity and immune escape. J Pathol. 2018;246(2):129–14. doi:10.1002/PATH.5139.
   PubMed Web of Science ®Google Scholar
• Lim SM, Choi JG, Cho SH, Kang EJ, Hwang IG, Yun T, Choi JW, Lee KW, Chang H, Kim JH, et al. Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma. Cancer Res Treat. 2019;51(1):300–312. doi:10.4143/crt.2018.012.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. 264. 2020. doi:10.1038/s41591-020-0805-8.
   PubMed Web of Science ®Google Scholar
• Trullas A, Delgado J, Genazzani A, Mueller-Berghaus J, Migali C, Müller-Egert S, Zander H, Enzmann H, Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. ESMO Open. 2021;6(3):100145. doi:10.1016/j.esmoop.2021.100145.
   PubMed Web of Science ®Google Scholar
• André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–2794. doi:10.1200/JCO.19.01021.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Salewski I, Kuntoff S, Kuemmel A, Feldtmann R, Felix SB, Henze L, Junghanss C, Maletzki C. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. Cancer Immunol Immunother. 2021;70(12):3405–3419. doi:10.1007/s00262-021-02933-4.
   PubMed Web of Science ®Google Scholar
• Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A, Berlin P, Henze L, Junghanss C, Maletzki C, et al. Combined gemcitabine and immune-checkpoint inhibition conquers Anti-PD-L1 resistance in low-immunogenic mismatch repair-deficient tumors. Int J Mol Sci. 2021;22(11):5990. doi:10.3390/IJMS22115990.
   PubMed Web of Science ®Google Scholar
• Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, et al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11(10):2564–2581. doi:10.1158/2159-8290.cd-20-1540.
   PubMed Web of Science ®Google Scholar
• Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2809–2817. doi:10.1016/j.celrep.2018.02.053.
   PubMed Web of Science ®Google Scholar
• Egelston C, Guo W, Yost S, Lee JS, Rose D, Avalos C, Ye J, Frankel P, Schmolze D, Waisman J, et al. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. J ImmunoTher Cancer. 2021;9(3):e002084. doi:10.1136/JITC-2020-002084.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Yap TA, Chung HC, de Miguel MJ, Bang Y-J, Lin C-C, Su W-C, Italiano A, Chow KH, Szpurka AM, et al. Safety and clinical activity of a New Anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the pact phase Ia/Ib trial. Clin Cancer Res. 2021;27(5):1267–1277. doi:10.1158/1078-0432.CCR-20-2821.
   PubMed Web of Science ®Google Scholar
• Salewski I, Henne J, Engster L, Krone P, Schneider B, Redwanz C, Lemcke H, Henze L, Junghanss C, Salewski I, et al. CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. Oncoimmunology. 2022;11(1). doi:10.1080/2162402X.2022.2094583
   PubMed Web of Science ®Google Scholar
• Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3) - PubMed.
   Google Scholar
• Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol. 2003;24(12):619–622. doi:10.1016/J.IT.2003.10.001.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J ImmunoTher Cancer. 2020;8(2):e001014. doi:10.1136/JITC-2020-001014.
   PubMed Web of Science ®Google Scholar
• Sordo‐Bahamonde C, Lorenzo‐Herrero S, González‐Rodríguez AP, Payer ÁR, González‐García E, López‐Soto A, Gonzalez S. LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia. Cancers Basel. 2021;13(9):2112. doi:10.3390/CANCERS13092112.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al. Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMOA2109970.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Tan DSW, Martín M, Ochoa-De-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J ImmunoTher Cancer. 2022;10(2):e003776. doi:10.1136/JITC-2021-003776.
   PubMed Web of Science ®Google Scholar
• Väyrynen JP, Haruki K, Lau MC, Väyrynen SA, Zhong R, Costa AD, Borowsky J, Zhao M, Fujiyoshi K, Arima K, et al. The prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol Res. 2021;9(1):8–19. doi:10.1158/2326-6066.CIR-20-0527.
   PubMed Web of Science ®Google Scholar
• Zhao R, Wan Q, Wang Y, Wu Y, Xiao S, Li Q, Shen X, Zhuang W, Zhou Y, Xia L, et al. M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer. Oncoimmunology. 2021;10(1). doi:10.1080/2162402X.2020.1862520
   Web of Science ®Google Scholar
• Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, Pangault C, Fest T, Ramla S, Jardin F, et al. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood. 2018;132(5):510–520. doi:10.1182/BLOOD-2017-12-819706.
   PubMed Web of Science ®Google Scholar
• He K, Liu X, Hoffman RD, Shi R, Lv G, Gao J. G-CSF / GM-CSF -induced hematopoietic dysregulation in the progression of solid tumors. FEBS Open Bio. 2022 Jul 9;12(7):1268–1285. doi:10.1002/2211-5463.13445.
   PubMed Web of Science ®Google Scholar
• Wildes TJ, DiVita Dean B, Flores CT. Myelopoiesis during solid cancers and strategies for immunotherapy. Cells. 2021;10(5):968. doi:10.3390/cells10050968.
   PubMed Web of Science ®Google Scholar
• Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell. 2022;40(6):674–693.e7. doi:10.1016/j.ccell.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou HJ, Rosulek A, Li H, Yang K, Fan K, Lipkin M, et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology. 2010;138(3):993–1002.e1. doi:10.1053/j.gastro.2009.11.009.
   PubMed Web of Science ®Google Scholar
• Kortüm B, Campregher C, Lang M, Khare V, Pinter M, Evstatiev R, Schmid G, Mittlböck M, Scharl T, Kucherlapati MH, et al. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice. Gut. 2015;64(12):1905–1912. doi:10.1136/gutjnl-2014-307663.
   PubMed Web of Science ®Google Scholar
• Maletzki C, Beyrich F, Hühns M, Klar E, Linnebacher M. The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget. 2016;7(33):53583–53598. doi:10.18632/oncotarget.10677.
   PubMedGoogle Scholar
• Gounari F, Khazaie K. TCF-1: a maverick in T cell development and function. Nat Immunol. 2022;23(5):671–678. doi:10.1038/S41590-022-01194-2.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu Q, Wei Y, Xiong Y, Gu Y, Huang Y, Tang F, Ouyang Y. Anterior gradient-2 regulates cell communication by coordinating cytokine–chemokine signaling and immune infiltration in breast cancer. Cancer Sci. 2023 Mar 17;114(6):2238–2253. doi:10.1111/CAS.15775.
   PubMed Web of Science ®Google Scholar
• Martisova A, Sommerova L, Krejci A, Selingerova I, Kolarova T, Zavadil Kokas F, Holanek M, Podhorec J, Kazda T, Hrstka R. Identification of AGR2 gene-specific expression patterns associated with epithelial-mesenchymal transition. Int J Mol Sci. 2022;23(18):10845. doi:10.3390/ijms231810845.
   PubMed Web of Science ®Google Scholar
• Yáñez A, Ng MY, Hassanzadeh-Kiabi N, Goodridge HS. IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production. Blood. 2015;125(9):1452–1459. doi:10.1182/BLOOD-2014-09-600833.
   PubMed Web of Science ®Google Scholar
• Al-Mterin MA, Murshed K, Elkord E. Correlations between circulating and tumor-infiltrating CD4+ Treg subsets with immune checkpoints in colorectal cancer patients with early and advanced stages. Vaccines. 2022;10(9):1471. doi:10.3390/VACCINES10091471.
   Web of Science ®Google Scholar
• Dercle L, Sun S, Seban R-D, Mekki A, Sun R, Tselikas L, Hans S, Bernard-Tessier A, Bouvier FM, Aide N, et al. Emerging and evolving concepts in cancer immunotherapy imaging. Radiology. 2022;306(1):32–46. doi:10.1148/RADIOL.210518.
   PubMed Web of Science ®Google Scholar
• Guan Y, Feng D, Yin B, Li K, Wang J. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Ther Adv Med Oncol. 2022;14:14. doi:10.1177/17588359221096877.
   Web of Science ®Google Scholar
• Decazes P, Bohn P. Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications. Cancers Basel. 2020;12(2):371. doi:10.3390/CANCERS12020371.
   PubMed Web of Science ®Google Scholar
• Santana-de Anda K, Gómez-Martín D, Díaz-Zamudio M, Alcocer-Varela J. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology. Autoimmunity Rev. 2011;11(2):98–103. doi:10.1016/J.AUTREV.2011.08.006.
   PubMed Web of Science ®Google Scholar
• Hu G, Barnes BJ. Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics. Expert Rev Anticancer Ther. 2014;6(5):775–784. doi:10.1586/14737140.6.5.775.
   Google Scholar
• Garcia-Marquez MA, Thelen M, Reinke S, Keller D, Wennhold K, Lehmann J, Veldman J, Borchmann S, Rosenwald A, Sasse S, et al. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia. 2022;36(3):760–771. doi:10.1038/S41375-021-01421-Z.
   PubMed Web of Science ®Google Scholar
• Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Sci Transl Med. 2021;13(608). doi:10.1126/SCITRANSLMED.ABF5107.
   Web of Science ®Google Scholar
• Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Ghassabeh GH, Raes G, De Baetselier P. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 2006;108(2):525–535. doi:10.1182/BLOOD-2005-09-3777.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184. doi:10.1186/S12943-022-01657-Y.
   PubMed Web of Science ®Google Scholar
• Koh J, Kim S, Woo YD, Song SG, Yim J, Han B, Lim S, Ahn HK, Mun S, Kim JS, et al. TCF1 + PD-1 + tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. Eur J Cancer. 2022;174:10–20. doi:10.1016/J.EJCA.2022.07.004.
   PubMed Web of Science ®Google Scholar
• Chen TW, Hung WZ, Chiang SF, Chen WTL, Ke TW, Liang JA, Huang CY, Yang PC, Huang KCY, Chao KSC. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett. 2022;543:543. doi:10.1016/J.CANLET.2022.215795.
   Web of Science ®Google Scholar
• Sio A, Chehal MK, Tsai K, Fan X, Roberts ME, Nelson BH, Grembecka J, Cierpicki T, Krebs DL, Harder KW. Dysregulated hematopoiesiscausedbymammary Cancer is associated with epigenetic changes and Hox gene expression in hematopoietic cells. Cancer Res. 2013;73(19):5892–5904. doi:10.1158/0008-5472.CAN-13-0842.
   PubMed Web of Science ®Google Scholar
• Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting Suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res. 2016;22(15):3849–3859. doi:10.1158/1078-0432.CCR-15-1912.
   PubMed Web of Science ®Google Scholar
• Valero JG, Matas-Céspedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, Guerrero-Hernández M, Yahiaoui A, Balagué O, Martin S, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;35(9):2635–2649. doi:10.1038/S41375-021-01201-9.
   PubMed Web of Science ®Google Scholar
• Riaz N, Burugu S, Cheng AS, Leung SCY, Gao D, Nielsen TO. Prognostic sgnificance of CSF-1R expression in early invasive breast cancer. Cancers Basel. 2021;13(22):5769. doi:10.3390/CANCERS13225769.
   PubMed Web of Science ®Google Scholar
• Li Z, Ding Y, Liu J, Wang J, Mo F, Wang Y, Chen-Mayfield TJ, Sondel PM, Hong S, Hu Q. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nat Commun. 2022;13(1):1–15. 2022 131. doi:10.1038/s41467-022-29388-0.
   PubMed Web of Science ®Google Scholar
• Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J ImmunoTher Cancer. 2022;10(5):e004076. doi:10.1136/JITC-2021-004076.
   PubMed Web of Science ®Google Scholar
• Abrams SI, Netherby CS, Twum DYF, Messmer MN. Relevance of interferon regulatory Factor-8 expression in myeloid-tumor interactions. J Interferon Cytokine Res. 2016;36(7):442–453. doi:10.1089/JIR.2015.0174.
   PubMed Web of Science ®Google Scholar
• Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A, Cortes Gomez E, Wang J, Nemeth MJ, Abrams SI. The granulocyte progenitor stage is a key target of IRF8-Mediated regulation of myeloid-derived suppressor cell production. J Immunol. 2017;198(10):4129–4139. doi:10.4049/JIMMUNOL.1601722.
   PubMed Web of Science ®Google Scholar
• Huang R-Y, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K, Huang R-Y, Eppolito C, Lele S, Shrikant P, et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8 + T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359–27377. doi:10.18632/ONCOTARGET.4751.
   PubMedGoogle Scholar
• Thudium K, Selby M, Zorn JA, Rak G, Wang X-T, Bunch RT, Hogan JM, Strop P, Korman AJ. Preclinical characterization of relatlimab, a human LAG-3–Blocking antibody, alone or in combination with Nivolumab. Cancer Immunol Res. 2022 Sep 16;10(10):1175–1189. doi:10.1158/2326-6066.CIR-22-0057.
   PubMed Web of Science ®Google Scholar